{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:37:13Z","timestamp":1790883433744,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["QUEST20PE0"],"award-info":[{"award-number":["QUEST20PE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SAWICK14PE1"],"award-info":[{"award-number":["SAWICK14PE1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T01:25:44Z","timestamp":1732238744000},"page":"187-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["What does it mean to be \u201chealthy\u201d when taking elexacaftor\/tezacaftor\/ivacaftor (ETI)? A qualitative study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-5436","authenticated-orcid":false,"given":"Robin S.","family":"Everhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Maggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeera","family":"Sconiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Yablon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Prickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callie","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6404-3793","authenticated-orcid":false,"given":"Alex H.","family":"Gifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-3512","authenticated-orcid":false,"given":"Kristin A.","family":"Riekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2024.11.003_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.003_bib0002","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/healthcare11010020","article-title":"The CFHealthHub learning health system: using real-time adherence data to support a community of practice to deliver continuous improvement in an archetypal long-term condition","volume":"11","author":"Sandler","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.jcf.2024.11.003_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40900-019-0159-x","article-title":"Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis","volume":"5","author":"Rowbotham","year":"2019","journal-title":"Res Involv Engagem"},{"issue":"7","key":"10.1016\/j.jcf.2024.11.003_bib0004","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.11.003_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/02770903.2016.1201835","article-title":"Perceptions and experiences underlying self-management and reporting of symptoms in teens with asthma","volume":"54","author":"Mammen","year":"2016","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.003_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00063198-199811000-00003","article-title":"Measurement of quality of life in cystic fibrosis","volume":"4","author":"Quittner","year":"1998","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.003_bib0007","doi-asserted-by":"crossref","first-page":"00120","DOI":"10.1183\/23120541.00120-2021","article-title":"The AWESCORE, a patient-reported outcome measure: development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis","volume":"7","author":"Button","year":"2021","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.003_bib0008","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jcf.2019.05.009","article-title":"Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)","volume":"18","author":"Gold","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.003_bib0009","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE Study group. Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: a Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232076","article-title":"A simple method to assess and report thematic saturation in qualitative research","volume":"15","author":"Guest","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.003_bib0011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"13","key":"10.1016\/j.jcf.2024.11.003_bib0012","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/jcm12134305","article-title":"Habituation to Pain in Patients with Chronic Pain: clinical Implications and Future Directions","volume":"12","author":"van der Miesen","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.003_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1049732308327348","article-title":"Normalization strategies of children with asthma","volume":"19","author":"Protudjer","year":"2009","journal-title":"Qual Health Res"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.003_bib0014","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s10897-012-9555-1","article-title":"Hoping to live a \"normal\" life whilst living with unpredictable health and fear of death: impact of cystic fibrosis on young adults","volume":"22","author":"Higham","year":"2013","journal-title":"J Genet Couns"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.003_bib0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2016.02.011","article-title":"Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes","volume":"15","author":"Borschuk","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.003_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2024.11.003_bib0017","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: healthcare providers' observations across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:15:09Z","timestamp":1778620509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324018113"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What does it mean to be \u201chealthy\u201d when taking elexacaftor\/tezacaftor\/ivacaftor (ETI)? A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}